Clinical trials
CAR-T Cell Therapy clinical trials
Below are recruiting car-t cell therapy clinical trials, each written for real people, not researchers. We’re tracking 525 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06768151RecruitingPhase 1
CEA-targeting car-t therapy for advanced lung cancer
This trial tests a new treatment called CAR-T therapy that targets a protein called CEA found on some lung cancer cells. It is for people with advanced lung cancer that has not responded to or has gotten worse after at least two standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07689058RecruitingPhase 2
CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Rawalpindi, Punjab ProvinceAges 18 years+ - NCT06680388RecruitingEarly Phase 1
CD19 CAR-T for severe autoimmune diseases
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT06027853RecruitingPhase 1
NK cell therapy for relapsed or refractory AML patients
This trial tests a natural killer (NK) cell therapy that targets a protein called CLL1 on leukemia cells. It aims to help people whose acute myeloid leukemia (AML) has come back or not responded to other treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06072989RecruitingPhase 1
B4T2-001 CAR-T infusions for solid tumors without chemo
This trial tests a new kind of cell therapy called CAR-T that targets a protein called BT-001 on solid tumors. It uses repeat infusions and avoids the strong chemotherapy usually given before treatment, which may be easier to tolerate.
Shanghai, China/ShanghaiAges 18–70 - NCT06903117RecruitingPhase 1
CAR T-Cell Therapy for CEA-Positive Advanced Lung Cancer
This early-stage trial tests a special immune cell treatment (CAR T cells) designed to target and attack lung cancer cells that have a protein called CEA on their surface. It's for people with advanced lung cancer who have already tried at least two standard treatments without success.
ShanghaiAges 18 years+ - NCT07641023RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Lung Cancer
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
Shenzhen, GuangdongAges 18–75 - NCT07106736RecruitingPhase 2
CAR-T for newly diagnosed multiple myeloma without transplant
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06316791RecruitingEarly Phase 1
CNCT19 CAR-T therapy for refractory autoimmune diseases
This early-phase study tests a new CAR-T cell therapy (CNCT19) for people with certain autoimmune diseases that have not responded to standard treatments. It targets a protein called CD19 on immune cells to help reset the immune system and reduce disease activity.
Zhengzhou, HenanAges 18–70 - NCT06793449RecruitingPhase 2
BCMA CAR-T vs. stem cell transplant for multiple myeloma
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
TianjinAges 18–70 - NCT05370430RecruitingPhase 1
CAR T therapy targeting BAFF-R for certain NHL
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
Duarte, CaliforniaAges 18 years+ - NCT06945523RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced lung cancer
This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.
Wuhan, HubeiAges 18 years+ - NCT07399769RecruitingPhase 1/Phase 2
MSLN CAR-T therapy for advanced solid tumors
This trial tests a new immune cell therapy called MSLN CAR-T for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help if your cancer has not responded to standard treatment and tests positive for a protein called mesothelin (MSLN).
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07306156RecruitingPhase 1/Phase 2
GP350 CAR-T for Epstein-Barr virus related lymphoma
This trial tests a new treatment called GP350 CAR-T for patients with lymphoma (a type of blood cancer) that has come back or not responded to standard therapy, especially when linked to Epstein-Barr virus (EBV) infection. The therapy uses your own immune cells, modified to target and kill cancer cells carrying the GP350 protein from EBV.
Hefei, AnhuiAges 18–70 - NCT07493044RecruitingPhase 1
Study of Super CAR-T for advanced liver cancer (GPC3-positive)
This trial tests a new cell therapy called Super CAR-T for people with advanced liver cancer that has GPC3 protein. It aims to see if the treatment is safe and effective. You may be eligible if your cancer has not responded to or stopped working on at least two standard treatments.
Guangzhou, GaungdongAges 18–75 - NCT06136364RecruitingPhase 1
CD7 CAR-T therapy for relapsed T-cell leukemia/lymphoma
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
ShanghaiAges 18–75 - NCT06821048RecruitingPhase 1
CAR-T cells targeting CEA for advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
Hangzhou, ZhejiangAges 18 years+ - NCT05255354Recruiting
Testing blood cancer DNA monitoring during CAR-T treatment
This trial checks whether a blood test that looks for small amounts of cancer DNA can accurately track minimal residual disease (MRD) in lymphoma patients during CAR-T therapy. It may help doctors detect relapse earlier and better judge how well CAR-T is working.
Palo Alto, CaliforniaAges 18 years+ - NCT07467863RecruitingPhase 1/Phase 2
Gene-modified immune cells for advanced lung cancer
This trial tests an experimental immune cell therapy (CAR-NK cells) that targets two to three specific markers on your lung cancer cells. It may be an option if your cancer has stopped responding to standard treatments and if tests show your tumor carries those markers.
Shenzhen, GuangdongAges 18–75 - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Gilbert, ArizonaAges 18 years+ - NCT07493395RecruitingPhase 2
CAR T-cell therapy for severe systemic sclerosis
This trial tests whether a special type of immune cell therapy, called CAR T-cells, can help people with severe systemic sclerosis (a disease causing skin and organ hardening) that hasn't improved with standard treatments. The goal is to see if it can stop the disease from getting worse.
LilleAges 18–64 - NCT06221553RecruitingPhase 1
New CAR T-cell treatment for DIPG brain tumor
This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.
Bangkok, PathumwanAges 1–18 - NCT07617805RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Head and Neck Cancer
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Shenzhen, GuangdongAges 18–75
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for car-t cell therapy?
- Yes. Clin2 currently lists 525 recruiting car-t cell therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a car-t cell therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a car-t cell therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.